The Motley Fool

Why I believe you can double your money with Footsie champion GlaxoSmithKline plc

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Scientist filling a needle
Image source: Getty Images.

GlaxoSmithKline (LSE: GSK) is one of the FTSE 100’s income champions. Despite stagnating earnings, over the past four years the company has paid out 80p per share annually to investors without fail for an average dividend yield over the period of 5.6%, around 1.8% higher than the FTSE 100 average over the period. 

However, recently shares in the pharmaceutical giant have come under pressure. Analysts have started to speculate that the group’s dividend record is under threat as new CEO Emma Walmsley eyes up possible acquisitions. 

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Buying growth 

Since 2012, Glaxo’s earnings have been treading water. The company reported earnings per share of 111p for 2012 then they fell to a low of 76p before rebounding to 102p last year. Analysts have pencilled in earnings per share of 110p for full-year 2017. 

Although other factors have contributed, the loss of exclusive manufacturing rights for the company’s blockbuster Advair drug has been responsible for the bulk of the earnings slide and Glaxo has also been underinvesting for years. The group’s research spend as a percentage of sales is less than 14% compared to its peer average of around 18%. AstraZeneca, Merck, and Bristol-Myers Squibb spent more than 25% of their revenues on R&D in 2016.

Walmsley wants to reverse this trend. She believes that Glaxo should move back to its scientific roots and search for the blockbuster drugs of the future. To this end, the new CEO has dropped 30 development programmes to focus on what she believes will be the real winners. 

She is also eyeing up acquisitions. Management has said it will take a look a Pfizer‘s consumer healthcare business as well as potentially acquiring the rest of the consumer joint venture it has with Novartis. Moreover, for the first time in over nine decades, the group has set up a team to look at smaller acquisitions in the domestic UK market. 

Cash flow crunch 

If Glaxo wants to ramp up spending, I believe management will have to cut the group’s dividend to free up cash. This might be unpalatable for income investors, but I think it will result in better long-term capital gains. 

As growth returns, the market should re-rate the stock to a more attractive multiple, producing potentially better returns than the current 5.9% dividend yield. For example, right now shares in Glaxo are trading at a forward P/E of 12.7 compared to the pharmaceuticals industry sector average of 18.8. If the market re-rates the stock on growth expectations up to the sector average, the shares could be worth 2,068p, a gain of 53% from current levels. 

Deals could help push the stock higher still. Pfizer’s consumer goods division generates around $3.4bn per annum in sales and a profit margin of around 20% suggests that this could boost Glaxo’s bottom line by around $700m, or approximately 10%. Buying the rest of the business with Novartis could add an extra 10% after extracting synergies. 

According to my figures, these deals could boost earnings per share to around 140p. At a sector average valuation, this implies a share price of more than 2,630p, nearly 100% above current levels. 

One Killer Stock For The Cybersecurity Surge

Cybersecurity is surging, with experts predicting that the cybersecurity market will reach US$366 billion by 2028more than double what it is today!

And with that kind of growth, this North American company stands to be the biggest winner.

Because their patented “self-repairing” technology is changing the cybersecurity landscape as we know it…

We think it has the potential to become the next famous tech success story.

In fact, we think it could become as big… or even BIGGER than Shopify.

Click here to see how you can uncover the name of this North American stock that’s taking over Silicon Valley, one device at a time…

Rupert Hargreaves owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.